[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第3页

[Clinical features of three cases with primary bone marrow lymphoma]. 【原发性骨髓淋巴瘤3例临床分析】。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.42

Hidetaka Nakagaki, Takahiro Shima, Reiko Yoneda, Masayasu Hayashi, Sae Utsumi, Seiya Hirakawa, Chiaki Kubara, Ken Takigawa, Akihisa Yoshino, Mariko Minami, Yayoi Matsuo, Takuro Kuriyama, Shuichi Taniguchi, Tetsuya Eto

{"title":"[Clinical features of three cases with primary bone marrow lymphoma].","authors":"Hidetaka Nakagaki, Takahiro Shima, Reiko Yoneda, Masayasu Hayashi, Sae Utsumi, Seiya Hirakawa, Chiaki Kubara, Ken Takigawa, Akihisa Yoshino, Mariko Minami, Yayoi Matsuo, Takuro Kuriyama, Shuichi Taniguchi, Tetsuya Eto","doi":"10.11406/rinketsu.66.42","DOIUrl":"10.11406/rinketsu.66.42","url":null,"abstract":"Primary bone marrow lymphoma (PBML) is a malignant lymphoma characterized by proliferation of lymphoma cells exclusively in the bone marrow without lymphadenopathy. Despite the dismal prognosis of PBML, it is a very rare lymphoma with limited evidence concerning its pathophysiology, making accumulation of cases important. We herein report three cases of PBML at our institution. The first patient was an 80-year-old man who presented with hemophagocytic syndrome and pancytopenia at admission, and died of septic shock during initial chemotherapy. The second patient was a 64-year-old man who achieved complete remission with intensive chemotherapies, but relapsed shortly after completing the final chemotherapy course. The third patient was a 66-year-old woman who underwent chemotherapies and allogeneic hematopoietic stem cell transplantation, only to relapse shortly after transplantation. Although early intervention with chemotherapy is essential for PBML treatment, diagnosis of PBML is very challenging due to the absence of lymph node involvement. Moreover, treatment outcomes of existing chemotherapy and transplantation therapies for PBML are still poor. Further accumulation of cases and development of new treatment strategies are desirable.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"42-48"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pharmacogenomics in leukemia treatment]. [白血病治疗中的药物基因组学]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.504

Motohiro Kato

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.860

引用次数: 0

[Novel treatment strategies for lower-risk myelodysplastic neoplasms]. [低风险骨髓增生异常肿瘤的新治疗策略]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.581

Yasuyoshi Morita

引用次数: 0

[Prevention and treatment of post-transplant relapse in adult T-cell leukemia-lymphoma]. 成人t细胞白血病-淋巴瘤移植后复发的预防与治疗

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.612

Ayumu Ito

{"title":"[Prevention and treatment of post-transplant relapse in adult T-cell leukemia-lymphoma].","authors":"Ayumu Ito","doi":"10.11406/rinketsu.66.612","DOIUrl":"https://doi.org/10.11406/rinketsu.66.612","url":null,"abstract":"Aggressive adult T-cell leukemia-lymphoma (ATL) is a rare T-cell malignancy with a poor prognosis. Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy, but the long-term survival rate is approximately 40%, which is poor compared to other hematopoietic tumors. The most common cause of death after allo-HCT is ATL relapse. Approximately 40% of patients experience a relapse following allo-HCT, and the prognosis after relapse remains poor. In recent years, various strategies have been attempted to prevent and treat post-transplant ATL relapse. Cord blood and HLA haplo-identical related donors are widely used as alternative donors to Japan Marrow Donor Program donors for transplantation in remission soon after diagnosis, and novel drugs for ATL are used as salvage therapy before or after allo-HCT. Monitoring of measurable residual disease with flow cytometry has also been attempted for early detection of post-transplant relapse. Nevertheless, there is still insufficient evidence for the prevention and treatment of post-transplant relapse of ATL. Given the limited experience at individual hospitals and the increasing population of HTLV-1 carriers throughout the country, it is desirable to build evidence based on treatment experience and analysis of clinical specimens from hospitals throughout Japan.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"612-620"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.718

引用次数: 0

[Development and performance evaluation of a comprehensive genomic profiling assay for hematological malignancies]. [血液学恶性肿瘤综合基因组分析方法的开发和性能评估]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.693

Yasunori Kogure, Yuji Oshikawa-Kumade, Suguru Fukuhara, Kenichi Chiba, Ai Okada, Motohiro Kato, Yasuhito Nannya, Mamiko Sakata-Yanagimoto, Masaki Ri, Takahiro Maeda, Hideki Muramatsu, Takayuki Ishikawa, Masashi Sanada, Yasunori Ueda, Daisuke Ennishi, Ryo Higashiyama, Daisuke Koga, Yuichi Shiraishi, Koji Izutsu, Keisuke Kataoka

{"title":"[Development and performance evaluation of a comprehensive genomic profiling assay for hematological malignancies].","authors":"Yasunori Kogure, Yuji Oshikawa-Kumade, Suguru Fukuhara, Kenichi Chiba, Ai Okada, Motohiro Kato, Yasuhito Nannya, Mamiko Sakata-Yanagimoto, Masaki Ri, Takahiro Maeda, Hideki Muramatsu, Takayuki Ishikawa, Masashi Sanada, Yasunori Ueda, Daisuke Ennishi, Ryo Higashiyama, Daisuke Koga, Yuichi Shiraishi, Koji Izutsu, Keisuke Kataoka","doi":"10.11406/rinketsu.66.693","DOIUrl":"https://doi.org/10.11406/rinketsu.66.693","url":null,"abstract":"Evaluation of genetic alterations is important for diagnosis, treatment selection, and prognostic assessment in hematological malignancies, but no comprehensive genomic profiling (CGP) assays for hematological malignancies have been approved for manufacturing and marketing in Japan. We have developed a CGP assay for the analysis of genetic alterations (specifically, mutations, structural variations, and fusion genes) in 452 genes, along with a corresponding analysis and reporting system that runs on Amazon Web Services. This CGP assay, named HemeSight®, successfully detected genetic alterations with an allele frequency of 5-10% in limit of detection testing using non-clinical samples. In testing using human clinical samples, it showed high positive percent agreement (94.4% for mutations, 94.7% for IGH rearrangements [structural variations], and 100% for fusion genes) compared with established clinical tests.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"693-704"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib]. [对变构BCR: ABL1抑制剂阿西米尼的耐药机制]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1033

Seiichi Okabe

{"title":"[Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib].","authors":"Seiichi Okabe","doi":"10.11406/rinketsu.66.1033","DOIUrl":"https://doi.org/10.11406/rinketsu.66.1033","url":null,"abstract":"Asciminib is a first-in-class allosteric inhibitor that specifically targets the myristoyl pocket of BCR::ABL1 and has shown efficacy in patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). Despite its unique mechanism of action, several resistance mechanisms to asciminib have been identified. BCR::ABL1 kinase domain mutations, including A337V, C464W, and compound mutations involving T315I, can interfere with asciminib binding or allosteric regulation. Additionally, BCR::ABL1 transcript variants lacking the SH3 domain, such as e13a3 and e14a3, exhibit primary resistance by disrupting the autoinhibited conformation required for asciminib activity. Non-BCR::ABL1 mechanisms that also contribute to resistance include overexpression of efflux transporters such as ABCG2 and P-glycoprotein, which reduce intracellular drug accumulation. Moreover, novel insertion mutations like p.I293_K294insSLLRD have been shown to impair the allosteric inhibition of ABL1. Combination therapies with ponatinib or other agents, as well as newer TKIs like olverembatinib, have demonstrated potential in overcoming resistance in preclinical and clinical models. Understanding these diverse resistance mechanisms is critical for optimizing asciminib-based treatment strategies and guiding the development of effective combination therapies for patients with resistant CML.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 9","pages":"1033-1041"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Treatment of pediatric chronic myeloid leukemia]. 小儿慢性髓性白血病的治疗。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1241

Chikako Tono

引用次数: 0

[Onco-cardiology in hematological malignancy: from the perspective of cardiology]. 血液病恶性肿瘤的肿瘤学-心脏病学：从心脏病学的角度看。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1094

Hiroshi Akazawa

引用次数: 0